Bringing it home: SA is leading the charge to make anti-HIV jab for Africa 

South Africa’s National Aids Council, Sanac, has asked local drug companies to submit applications by April 7 to make generic versions of an anti-HIV jab that could end Aids by 2043 in the country. The original version of the once-every-six-months shot, known as lenacapavir, is produced by the US pharmaceutical company, Gilead Sciences. Sanac will submit a shortlist of successful applicants, who met the requirements of the Council’s expression of interest call, to Gilead by July.

By Eyaaz